Biotech ETF Rises 17% in a Month Without NVIDIA
A biotech ETF posts a 17% gain in the trailing month even as NVIDIA weakens, underscoring a sector rotation that chal...
Index funds offer a simple, cost-efficient path to retirement growth, combining broad market exposure with minimal management. This overview explains the appeal.
22,512 articlesA biotech ETF posts a 17% gain in the trailing month even as NVIDIA weakens, underscoring a sector rotation that chal...
ARTY leads humanoid-robot ETFs in 2026, outpacing BOTT and ROBO as investors chase AI software momentum. This shift h...
SpaceX’s public debut has revived a long-standing fight over dual-class voting. Investors and watchdogs are weighing ...
A hedge fund manager publicly admits that his temperament blocks Buffett-style value investing. The admission highlig...
Retail investors flock to a $50-priced ETF that looks like a safe cash substitute as rate expectations shift. Here’s ...
The market looks frothy: moves are shaping how I protect gains without giving up long-term growth. Here are three con...
A Goldman Sachs strategist warns that leverage is rising across retail investors, hedge funds, and leveraged ETFs, po...
As U.S. markets face volatility, a single low-cost ETF offering broad exposure to Europe and Japan is drawing steady ...
A $7.6 billion ETF focused on smart grid infrastructure charges a 0.56% fee to capture AI power demand, centering on ...
Two tech giants stand out for investors seeking value in megacap stocks. This guide breaks down strengths, risks, and...
AI-driven data centers are lifting utility ETFs higher as power demand climbs. This report analyzes leading funds and...
Warren Buffett's successor, Greg Abel, is drawing new attention as recent 13F filings hint at a shift in Berkshire's ...